CATX Valuation

Perspective Therapeutics Inc

Add to Watchlist

Advanced Chart

3.360

-0.02(-0.592%)1D

Overview
Forecast
Valuation
Earnings

CATX Relative Valuation

CATX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CATX is overvalued; if below, it's undervalued.

Historical Valuation

Perspective Therapeutics Inc (CATX) is now in the Fair zone, suggesting that its current forward PS ratio of 12.41 is considered Fairly compared with the five-year average of -13.69. The fair price of Perspective Therapeutics Inc (CATX) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：3.38

Fair

-2.50

Trailing

Forward

-0.61

EV/EBITDA

Perspective Therapeutics Inc. (CATX) has a current EV/EBITDA of -0.61. The 5-year average EV/EBITDA is -5.82. The thresholds are as follows: Strongly Undervalued below -31.40, Undervalued between -31.40 and -18.61, Fairly Valued between 6.98 and -18.61, Overvalued between 6.98 and 19.77, and Strongly Overvalued above 19.77. The current Forward EV/EBITDA of -0.61 falls within the Historic Trend Line -Fairly Valued range.

-0.58

EV/EBIT

Perspective Therapeutics Inc. (CATX) has a current EV/EBIT of -0.58. The 5-year average EV/EBIT is -41.29. The thresholds are as follows: Strongly Undervalued below -300.87, Undervalued between -300.87 and -171.08, Fairly Valued between 88.51 and -171.08, Overvalued between 88.51 and 218.30, and Strongly Overvalued above 218.30. The current Forward EV/EBIT of -0.58 falls within the Historic Trend Line -Fairly Valued range.

449.92

Perspective Therapeutics Inc. (CATX) has a current PS of 449.92. The 5-year average PS is 211.32. The thresholds are as follows: Strongly Undervalued below -800.81, Undervalued between -800.81 and -294.74, Fairly Valued between 717.39 and -294.74, Overvalued between 717.39 and 1223.45, and Strongly Overvalued above 1223.45. The current Forward PS of 449.92 falls within the Historic Trend Line -Fairly Valued range.

-2.90

P/OCF

Perspective Therapeutics Inc. (CATX) has a current P/OCF of -2.90. The 5-year average P/OCF is -7.95. The thresholds are as follows: Strongly Undervalued below -42.49, Undervalued between -42.49 and -25.22, Fairly Valued between 9.31 and -25.22, Overvalued between 9.31 and 26.58, and Strongly Overvalued above 26.58. The current Forward P/OCF of -2.90 falls within the Historic Trend Line -Fairly Valued range.

-4.73

P/FCF

Perspective Therapeutics Inc. (CATX) has a current P/FCF of -4.73. The 5-year average P/FCF is 2.89. The thresholds are as follows: Strongly Undervalued below -21.62, Undervalued between -21.62 and -9.37, Fairly Valued between 15.14 and -9.37, Overvalued between 15.14 and 27.40, and Strongly Overvalued above 27.40. The current Forward P/FCF of -4.73 falls within the Historic Trend Line -Fairly Valued range.

Perspective Therapeutics Inc (CATX) has a current Price-to-Book (P/B) ratio of 0.94. Compared to its 3-year average P/B ratio of 1.56 , the current P/B ratio is approximately -39.39% higher. Relative to its 5-year average P/B ratio of 2.19, the current P/B ratio is about -56.94% higher. Perspective Therapeutics Inc (CATX) has a Forward Free Cash Flow (FCF) yield of approximately -42.82%. Compared to its 3-year average FCF yield of -18.63%, the current FCF yield is approximately 129.77% lower. Relative to its 5-year average FCF yield of -14.30% , the current FCF yield is about 199.32% lower.

0.94

P/B

Median3y

1.56

Median5y

2.19

-45.73

FCF Yield

Median3y

-18.63

Median5y

-14.30

Competitors Valuation Multiple

The average P/S ratio for CATX's competitors is 183.27, providing a benchmark for relative valuation. Perspective Therapeutics Inc Corp (CATX) exhibits a P/S ratio of 449.92, which is 145.50% above the industry average. Given its robust revenue growth of -44.87%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

CATX.A

Perspective Therapeutics Inc

Alpha Tau Medical Ltd

Shoulder Innovations Inc

6.42

41.04%

299.79M

Performance Decomposition

Market capitalization of CATX decreased by 78.61% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -2.13K to -7.59K.

The secondary factor is the Revenue Growth, contributed -44.87%to the performance.

Overall, the performance of CATX in the past 1 year is driven by Margin Expansion. Which is more sustainable.

-44.87%

526.00K → 290.00K

Revenue Growth

255.82%

-2.13K → -7.59K

Margin Expansion

-289.56%

1.34 → -2.54

P/E Change

-78.61%